This newsletter presents you the following key sessions:
1. Video interview with Hedy L. Kindler, MD, FASCO about Olaparib delays progression of metastatic pancreatic
cancer in patients with BRCA mutation
2. Less toxic TPEx regimen possible new option for patients in first-line recurrent/metastatic head and neck
squamous cell carcinoma
3. Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-
sensitive prostate cancer
4. Ramucirumab plus erlotinib improves progression-free survival in EGFR-positive lung cancer
5. Doxorubicin + olaratumab is not superior to doxorubicin + placebo in patients with advanced soft tissue
sarcomas
